Abstracts tagged "Antibodies"

Abstract Number: 2362 • 2015 ACR/ARHP Annual Meeting
Rituximab in the Treatment of Jo-1 Antibody-Associated Antisynthetase Syndrome: Anti-Ro52 Positivity As a Marker for Severity and Treatment Response
Jutta Bauhammer¹, Norbert Blank², Hanns-Martin Lorenz³, Regina Max⁴, Dietmar Krause⁵ and Christoph Fiehn¹, ¹ACURA Centre for Rheumatic Diseases, Baden-Baden, Germany, ²Dept. of Internal Medicine 5, Division of Rheumatology, University of Heidelberg, Heidelberg, Germany, ³Department of Internal Medicine 5, Division of Rheumatology, University of Heidelberg, Heidelberg, Germany, ⁴Dept. of Internal Medicine 5, Division of Rheumatology, University of Heidelberg, Heidelberg, Germany, ⁵Dept. of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum, Bochum, Germany
Background/Purpose: Rituximab (RIX) has successfully been used for the treatment of severe Jo-1 antibody-associated antisynthetase syndrome (Jo-1 ASS). The aim of this retrospective study was…
Abstract Number: 405 • 2015 ACR/ARHP Annual Meeting
Anti-C1q Antibodies As Potential Diagnostic and Prognostic Biomarkers in Juvenile Systemic Lupus Erythematosus
Thaschawee Arkachaisri^1,2, Justin Hung Tiong Tan¹, Manasita Tanya¹, Sook Fun Hoh³, Lena Das⁴ and Jing Yao Leong^5,6, ¹Rheumatology and Immunology, KK Women's and Children's Hospital, Singapore, Singapore, ²Paediatrics, Duke-NUS Graduate Medical School, Singapore, Singapore, ³Nursing, KK Women's and Children's Hospital, Singapore, Singapore, ⁴Dept of Rheumatology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ⁵Duke-National University of Singapore Graduate Medical School, Singapore, Singapore, ⁶SingHealth Translational Immunology and Inflammation Centre, Singapore Health Services Pte Ltd, Singapore, Singapore
Background/Purpose: Anti-C1q antibodies (AC1q) were shown to strongly correlate with the occurrence and activity of lupus nephritis in adult SLE. Data of the antibodies in…
Abstract Number: 2367 • 2015 ACR/ARHP Annual Meeting
Risk of Malignancy in Dermatomyositis with Anti-CADM-140/ Melanoma Differentiation- Associated Gene 5 Autoantibody
Shinji Sato¹, Takayoshi Kurabayashi¹, Sho Sasaki², Yasushi Koyama², Shinichi Nogi³, Naofumi Chinen¹, Chiho Yamada¹ and Yasuo Suzuki¹, ¹Internal Medicine/ Rheumatology, Tokai University School of Medicine, Isehara, Japan, ²Internal Medicine/Rheumatology, Tokai University School of Medicine, Isehara, Japan, ³Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan
Background/Purpose: Anti-CADM-140/ Melanoma Differentiation-Associated Gene 5 (MDA5) antibody is found specifically in patients with dermatomyositis (DM). This autoantibody is associated with clinically amyopathic DM (CADM)…
Abstract Number: 483 • 2015 ACR/ARHP Annual Meeting
Antibody to Malondialdehyde-Acetaldehyde (MAA) Adducts Serve As Biomarkers of Treatment Response in Rheumatoid Arthritis
Ted R. Mikuls¹, Brian Coburn¹, Harlan Sayles², Fang Yu³, Mary Brophy⁴, James R. O'Dell¹, Lynell W. Klassen⁵ and Geoffrey M. Thiele¹, ¹Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Public Health, University of Nebraska Medical Center, Omaha, NE, ⁴VA Boston Heathcare System, Boston, MA, ⁵Dept of Internal Medicine, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Previous reports have demonstrated that malondialdehyde-acetaldehyde (MAA) adducts are produced as a byproduct of oxidative stress and lipid peroxidation and are expressed in…
Abstract Number: 2376 • 2015 ACR/ARHP Annual Meeting
Clinical Features in Dermatomyositis Patients with Novel Autoantibody to Small Ubiquitin-like Modifier Activating Enzymes (Anti-SAE Antibody) and Relationship to Interstitial Lung Disease: A Systematic Review of 29 Cases
Sirada Panupattanapong¹, Jessica Sun² and Kevin Baszis¹, ¹Pediatrics, Division of Rheumatology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO, ²Pediatric, Division of Rheumatology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO
Background/Purpose: Anti-SAE antibody is a novel myositis-specific antibody first described in 2007. SAE is an enzyme that facilitates sumoylation, leading to the formation of stable…
Abstract Number: 534 • 2015 ACR/ARHP Annual Meeting
Antibodies to Malondialdehyde-Acetaldehyde Adducts Are Highly Expressed in Rheumatoid Arthritis Synovial Fluid
Rafid Rahman¹, Geoffrey M. Thiele², Andy Hollins³, Michael J. Duryee¹, Daniel Anderson³, Bartlett Hamilton⁴, Kaleb Michaud⁵, Lynell W. Klassen⁶ and Ted R. Mikuls³, ¹Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ³University of Nebraska Medical Center, Omaha, NE, ⁴University of Nebraska Medical Center and Omaha VA Medical Center, Omaha, NE, ⁵Rheumatology & Immunology, University of Nebraska Medical Center and National Data Base for Rheumatic Diseases, Omaha, NE, ⁶Dept of Internal Medicine, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Malondialdehyde-acetaldehyde (MAA) adducts are expressed in synovial tissues in rheumatoid arthritis (RA). Post-translational MAA modifications are pro-inflammatory, promoting robust anti-MAA antibody responses that…
Abstract Number: 2515 • 2015 ACR/ARHP Annual Meeting
MEK5/ERK5, a Lynchpin of Human Cardiac Fibroblast Transdifferentiation to a Scarring Phenotype in Autoimmune Congenital Heart Block
Andrew Markham¹, Robert Clancy², Mukundan Attur³ and Jill P. Buyon², ¹Medicine, New York University School of Medicine, New York, NY, ²Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Rheumatology Research, NYU - Hospital for Joint Diseases, New York, NY
Background/Purpose: Transplacental passage of maternal autoantibodies (Ab) reactive with the SSA/Ro-SSB/La ribonucleoprotein complex is associated with the development of cardiac injury in the fetus passively…
Abstract Number: 589 • 2015 ACR/ARHP Annual Meeting
Adalimumab Concentration at 16 Weeks of Treatment Is Associated with Treatment Discontinuation within One Year
Mieke F. Pouw^1,2, Denis Mulleman³, Mike T. Nurmohamed^1,4, Theo Rispens⁵, Gilles Paintaud³, Gertjan Wolbink^1,2 and David Ternant³, ¹Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²Immunopathology, Sanquin Research, Amsterdam, Netherlands, ³Université François-Rabelais de Tours, CNRS 7292, Tours, France, Tours, France, ⁴Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁵Sanquin Research, Amsterdam, Netherlands
Background/Purpose: Anti-drug antibodies (ADAb) in patients treated with adalimumab have been associated with decreased adalimumab concentrations and loss of clinical response, and therefore treatment discontinuation.…
Abstract Number: 2551 • 2015 ACR/ARHP Annual Meeting
Antibodies to Malondialdehyde-Acetaldhyde Adducts Are Increased in the Serum of Mice Following Infection with P. Gingivalis and/or Injection of Citrullinated Mouse Type II Collagen: a Model of Human Disease Response
Geoffrey M. Thiele⁴, Einstein Juma¹, Roxanne Haslam¹, Michael J. Duryee², Anand Dusad³, Carlos D. Hunter², James R. O'Dell⁴, Lynell W. Klassen⁴, Ted R. Mikuls⁴ and Geoffrey M. Thiele⁴, ¹University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with RA complicated by periodontal disease (PD) have been shown to have higher anti-citrullinated protein antibody (ACPA) levels, which have also become predictive…
Abstract Number: 632 • 2015 ACR/ARHP Annual Meeting
Isolated Atrioventricular Block of Unknown Origin in the Adult and Autoimmunity: Diagnostic and Therapeutic Considerations Exemplified By Three Anti-Ro/SSA-Associated Cases
Antonio Brucato¹, Pietro Enea Lazzerini², Pier Leopoldo Capecchi³, Anna Valenti⁴, Lucia Baldi⁵, Maria Romana Bacarelli³, Claudia Nucci⁵, Valentina Moscadelli³, Gabriella Morozzi³, Mohamed Butjdir^6,7,8 and Franco Laghi Pasini³, ¹Internal Medicine, Ospedale Papa Giovanni XXIII Bergamo, Bergamo, Italy, ²Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy, ³Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy, ⁴Internal Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy, ⁵Cardiology, University of Siena, Siena, Italy, ⁶Medicine, Cell Biology and Pharmacology, State University of New York at Downstate Medical Center, New York, NY, ⁷NYU School of Medicine, New York, NY, ⁸Research Department, VA New York Harbor Healthcare System, New York, NY
Background/Purpose: Circulating anti-Ro/SSA antibodies may rarely affect the adult conduction-system. A direct autoantibody-mediated electrophysiological inhibition of cardiomyocyte calcium-channels (acquired form) or an ante-natal subclinical injury…
Abstract Number: 2922 • 2015 ACR/ARHP Annual Meeting
HLA-Specific Antibody Profile in Renal Transplant Patients with Systemic LUPUS Erythematosus
Diana Girnita¹, Paul Brailey² and Alin Girnita³, ¹Division of Immunology, Allergy & Rheumatology, University of Cincinnati Medical Center, Cincinnati, OH, ²Transplant Immunology Division, University of Cincinnati Medical Center -Hoxworth Blood Center, cincinnati, OH, Oman, ³Transplant Immunology Division, University of Cincinnati Academic Health Center, Hoxworth Blood Center, Cincinnati, OH
Background/Purpose: End stage renal disease due to Systemic lupus erytematosus (SLE) is one of the autoimmune disorder leading to renal transplantation. In this single-center study…
Abstract Number: 633 • 2015 ACR/ARHP Annual Meeting
Anti-Centromere Antibodies Are Associated with More Severe Exocrine Glandular Dysfunction in Primary Sjögren’s Syndrome: An Analysis of the Sjögren’s International Collaborative Clinical Alliance Cohort
Alan N. Baer¹, Leah Medrano² and Mara McAdams-Demarco³, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ³Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
Background/Purpose: Anti-centromere antibodies (ACA) define a subgroup of Sjögren’s syndrome (SS) patients who are often older, have more frequent Raynaud’s phenomenon, and a lower frequency…
Abstract Number: 2951 • 2015 ACR/ARHP Annual Meeting
Anti-NR2 Antibody and Blood-Brain Barrier Disruption in Systemic Lupus Erythematosus Patients with Cognitive Dysfunction
Gaurav Gulati¹, Philip Iffland², Damir Janigro², Bin Zhang³ and Michael Luggen⁴, ¹Division of Immunology, Allergy and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH, ²Cleveland Clinic Lerner College of Medicine, Cleveland, OH, ³Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ⁴Division of Immunology, University of Cincinnati Medical Center, Cincinnati, OH
Background/Purpose: Cognitive Dysfunction (CD) is one of the most common manifestations of neuropsychiatric SLE (NPSLE) and one of the most devastating. The pathogenesis of CD…
Abstract Number: 635 • 2015 ACR/ARHP Annual Meeting
Seronegative Sjögren’s Syndrome Is Associated with a Higher Frequency of Patient-Reported Neuropathic Pain: An Analysis of the Sjögren’s International Collaborative Clinical Alliance Cohort
Alan N. Baer¹ and Julius Birnbaum², ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Patients with Sjögren’s syndrome (SS) and negative SSA/SSB serology (ie. seronegative SS) have phenotypic characteristics different than seropositive ones, and thus may constitute a…
Abstract Number: 3112 • 2015 ACR/ARHP Annual Meeting
Incidence of Anti-Drug Antibodies in Rheumatoid Arthritis Patients Treated with Adalimumab, Etanercept, or Infliximab in a Real-World Setting
RJ Moots¹, Ricardo Xavier², Chi Chiu Mok³, Mahboob U Rahman⁴, Wen-Chan Tsai⁵, Mustafa Al Maini⁶, Karel Pavelka⁷, Ehab Mahgoub⁸, Sameer Kotak⁹, Joan Korth-Bradley¹⁰, Ronald Pedersen¹¹, Linda Mele⁸, Qi Shen⁸ and Bonnie Vlahos⁸, ¹Department of Musculoskeletal Biology, University of Liverpool, Liverpool, United Kingdom, ²Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, ³Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ⁴Perelman School of Medicine, University of Pennsylvania, Philadephia, PA, ⁵Kaohsiung Medical University, Kaohsiung, Taiwan, ⁶Rheumatology, Allergy and Clinical Immunology Division, Mafraq Hospital, Abu Dhabi, United Arab Emirates, ⁷Charles University, Prague, Czech Republic, ⁸GIPB - Clinical Sciences, Pfizer, Collegeville, PA, ⁹Global Health and Value, Pfizer, New York, NY, ¹⁰GIPB- Clinical Sciences, Pfizer, Collegeville, PA, ¹¹Department of Biostatistics, Pfizer, Collegeville, PA
Background/Purpose: Treatment with biologics can elicit unwanted immune responses such as antidrug antibodies (ADA), which may decrease their clinical efficacy and increase adverse events. However,…

« Previous Page
1
…
3
4
5
6
7
…
9
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].